Completed PHASE2 INTERVENTIONAL 3-arm NCT01033344

Cat-PAD Exposure Chamber Study

A Double-blind, Randomized, Placebo-controlled Study to Evaluate Two Treatment Regimens of Cat-PAD in Cat Allergic Subjects Following Challenge to Cat Allergen in an Environmental Exposure Chamber

Sponsor: Adiga Life Sciences, Inc.

Conditions Cat Allergy

Interventions Cat-PAD Placebo

Updated 5 times since 2017 Last updated: Sep 30, 2010 Started: Jan 31, 2010 Primary completion: Sep 30, 2010 Completion: Sep 30, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Cat Allergy and is currently completed. Adiga Life Sciences, Inc. leads this study, which shows 5 recorded versions since 2010 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Jan 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Adiga Life Sciences, Inc.
Cetero Research, San Antonio
Circassia Limited

Data source: Circassia Limited

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Mississauga, Canada